Eli Lilly Ends Covid-19 Antibody Trial After Finding It’s Unlikely To Help Hospitalized Patients

Eli Lilly said Monday that it will end a U.S.-based clinical trial for its coronavirus antibody treatment because the data indicates the treatment is unlikely to help coronavirus patients recover from advanced stages of the disease, a move which comes two weeks after it paused the trial citing a potential safety concern.